Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (NASDAQ:TXG), filed a Form 4 on August 26, 2026, reporting the sale of Class A Common Stock on August 24, 2026, to cover tax withholding obligations connected to the vesting of restricted stock units.

Key Highlights

  • Reporting person: Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc.
  • Shares sold: 13,818 shares of Class A Common Stock disposed of on August 24, 2026.
  • Weighted average price: $63.0236 per share, with individual trades ranging from $63.0088 to $63.78, inclusive.
  • Purpose of sale: Shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units, according to the filing.
  • Remaining ownership: Hindson directly beneficially owned 488,182 shares of Class A Common Stock following the reported transaction.
  • Filing signed: Randy Wu, as Attorney-in-Fact for Benjamin J. Hindson, signed the form on August 26, 2026.

Hindson RSU Vesting Triggers Tax-Related Share Disposal at 10x Genomics

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Benjamin J. Hindson, who serves as both a Director and as President and Chief Scientific Officer of 10x Genomics, Inc., disposed of 13,818 shares of Class A Common Stock on August 24, 2026. The filing identifies the transaction code as "S" and classifies the shares as disposed of (D) through a direct ownership arrangement.

The filing states that the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The reported weighted average sale price was $63.0236 per share. The transaction was executed across multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The filing notes that Hindson "undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."

Following the reported transaction, Hindson directly held 488,182 shares of Class A Common Stock, according to the filing. No derivative securities transactions were reported in Table II of the form. The filing was signed by Randy Wu as Attorney-in-Fact for Benjamin J. Hindson on August 26, 2026.

What Was Disclosed

The Form 4 discloses the sale of 13,818 shares of Class A Common Stock by 10x Genomics President and Chief Scientific Officer Benjamin J. Hindson on August 24, 2026, at a weighted average price of $63.0236, solely to satisfy tax withholding obligations upon RSU vesting.